DK3078372T3 - Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor - Google Patents
Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor Download PDFInfo
- Publication number
- DK3078372T3 DK3078372T3 DK16169414.6T DK16169414T DK3078372T3 DK 3078372 T3 DK3078372 T3 DK 3078372T3 DK 16169414 T DK16169414 T DK 16169414T DK 3078372 T3 DK3078372 T3 DK 3078372T3
- Authority
- DK
- Denmark
- Prior art keywords
- benzopyran
- oxo
- phenoxy
- amino
- pain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Claims (9)
1. Benzopyranderivat til anvendelse ved behandling af neuropatisk smerte, hvor benzopyranderivatet er repræsenteret af den følgende almene formel, eller et salt deraf, Formel I
hvor R1 repræsenterer en eventuelt substitueret Ci-6-alkylgruppe; en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer et hydrogenatom, en eventuelt substitueret aminogruppe, en eventuelt substitueret acylaminogruppe, en eventuelt substitueret cabamoylgruppe eller en eventuelt substitueret arylgruppe.
2. Benzopyranderivat til anvendelse ifølge krav 1, hvor en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer en eventuelt substitueret acylaminogruppe.
3. Benzopyranderivat til anvendelse ifølge krav 1, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for-mamid, N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methansulfon-amid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]-acetamid, N-(4-oxo-6-phenoxy-4H-1 -benzopyran-7-yl)methansulfonamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-carboxamid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-yl]acetamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-carboxamid, N-[7-[(ethylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamid eller N-(4-oxo-6-phenoxy-2-phenyl-4H-1-benzopyran-7-yl)methansulfonamid.
4. Benzopyranderivat til anvendelse ifølge krav 1, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for-mamid.
5. Behandlingsmiddel til anvendelse ved behandling af neuropatisk smerte, hvor behandlingsmidlet omfatter et benzopyranderivat repræsenteret ved den følgende formel, eller et salt deraf, Formel 2
hvor R1 repræsenterer en eventuelt substitueret Ci-6-alkylgruppe; en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer et hydrogenatom, en eventuelt substitueret aminogruppe, en eventuelt substitueret acylaminogruppe, en eventuelt substitueret cabamoylgruppe eller en eventuelt substitueret arylgruppe.
6. Behandlingsmiddel til anvendelse ifølge krav 5, hvor en af R2 og R3 repræsenterer et hydrogenatom; og den anden af R2 og R3 repræsenterer en eventuelt substitueret acylaminogruppe.
7. Behandlingsmiddel til anvendelse ifølge krav 5, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for-mamid, N-(3-amino-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl)methansulfon-amid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]-acetamid, N-(4-oxo-6-phenoxy-4H-1 -benzopyran-7-yl)methansulfonamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-carboxamid, N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-2-yl]acetamid, 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-carboxamid, N-[7-[(ethylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamid eller N-(4-oxo-6-phenoxy-2-phenyl-4H-1-benzopyran-7-yl)methansulfonamid.
8. Behandlingsmiddel til anvendelse ifølge krav 5, hvor benzopyranderivatet er N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]for- mamid.
9. Behandlingsmiddel til anvendelse ifølge et af kravene 5 til 8, hvor den neu-ropatiske smerte er fibromyalgi, postherpetisk smerte, diabetisk neuropati, smerter relateret til post-rygmarvsskade, postapoplektisk smerte, kronisk smerte, komplekst regionalt smertesyndrom, rygsmerter, som NSAID'er ikke er tilstrækkeligt virksomme for, ischias, bækkenbundssmerter, trigeminal neuralgi, osteoarthritis-smerter, som NSAID'er ikke er tilstrækkeligt virksomme for, deafferenterings-smertesyndrom, smerte forårsaget af myositis, smerte forårsaget af fasciitis, og smerte forårsaget af seronegativ arthritis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013149690 | 2013-07-18 | ||
| EP14826811.3A EP2929880B1 (en) | 2013-07-18 | 2014-07-17 | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3078372T3 true DK3078372T3 (da) | 2017-10-16 |
Family
ID=52346269
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16169414.6T DK3078372T3 (da) | 2013-07-18 | 2014-07-17 | Terapeutisk middel mod sygdom på basis af hæmmende virkning af makrofag-migrationshæmmende faktor |
| DK14826811.3T DK2929880T3 (da) | 2013-07-18 | 2014-07-17 | Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14826811.3T DK2929880T3 (da) | 2013-07-18 | 2014-07-17 | Terapeutisk middel til sygdom baseret på hæmmende effekt af makrofag-migrationshæmmende faktor |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20150353519A1 (da) |
| EP (2) | EP3078372B1 (da) |
| JP (2) | JP5802868B2 (da) |
| CN (1) | CN105407887B (da) |
| AU (1) | AU2014291149B2 (da) |
| CA (1) | CA2918325C (da) |
| CY (2) | CY1118140T1 (da) |
| DK (2) | DK3078372T3 (da) |
| ES (2) | ES2642440T3 (da) |
| HR (2) | HRP20161317T1 (da) |
| HU (2) | HUE034661T2 (da) |
| IL (1) | IL243550B (da) |
| LT (2) | LT2929880T (da) |
| NO (1) | NO3078372T3 (da) |
| PL (2) | PL2929880T3 (da) |
| PT (2) | PT2929880T (da) |
| RS (2) | RS55394B1 (da) |
| RU (2) | RU2750540C2 (da) |
| SI (2) | SI2929880T1 (da) |
| SM (3) | SMT201700080T1 (da) |
| TW (1) | TWI603965B (da) |
| WO (1) | WO2015008827A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018137708A1 (zh) * | 2017-01-26 | 2018-08-02 | 重庆莱美药业股份有限公司 | 一种纳米炭-铁复合体系及其组合物、制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| US5922755A (en) * | 1993-04-09 | 1999-07-13 | Toyama Chemical Co., Ltd. | Immunomodulator, cell adhesion inhibtor, and agent for treating, and preventing autoimmune diseases |
| WO1997023714A1 (de) * | 1995-12-21 | 1997-07-03 | Siemens Aktiengesellschaft | Luftansaugvorrichtung mit variabler saugrohrlänge für eine brennkraftmaschine |
| DE10044091A1 (de) * | 2000-09-07 | 2002-04-04 | Merck Patent Gmbh | Chromanonderivate |
| GB0507696D0 (en) * | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| GB0507695D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| BR112014002407A2 (pt) | 2011-08-30 | 2017-02-21 | Toyama Chemical Co Ltd | método para melhorar a terapia contra doenças autoimunes tais como artrite reumatóide |
-
2014
- 2014-07-17 NO NO16169414A patent/NO3078372T3/no unknown
- 2014-07-17 SI SI201430088A patent/SI2929880T1/sl unknown
- 2014-07-17 SM SM20170080T patent/SMT201700080T1/it unknown
- 2014-07-17 PT PT148268113T patent/PT2929880T/pt unknown
- 2014-07-17 US US14/647,931 patent/US20150353519A1/en not_active Abandoned
- 2014-07-17 HU HUE16169414A patent/HUE034661T2/en unknown
- 2014-07-17 RS RS20161048A patent/RS55394B1/sr unknown
- 2014-07-17 EP EP16169414.6A patent/EP3078372B1/en active Active
- 2014-07-17 AU AU2014291149A patent/AU2014291149B2/en not_active Ceased
- 2014-07-17 ES ES16169414.6T patent/ES2642440T3/es active Active
- 2014-07-17 JP JP2015527333A patent/JP5802868B2/ja not_active Expired - Fee Related
- 2014-07-17 RU RU2017131951A patent/RU2750540C2/ru active
- 2014-07-17 LT LTEP14826811.3T patent/LT2929880T/lt unknown
- 2014-07-17 RU RU2016105141A patent/RU2641301C2/ru active
- 2014-07-17 SI SI201430469T patent/SI3078372T1/en unknown
- 2014-07-17 HU HUE14826811A patent/HUE029800T2/en unknown
- 2014-07-17 PT PT161694146T patent/PT3078372T/pt unknown
- 2014-07-17 CA CA2918325A patent/CA2918325C/en active Active
- 2014-07-17 SM SM20170606T patent/SMT201700606T1/it unknown
- 2014-07-17 HR HRP20161317TT patent/HRP20161317T1/hr unknown
- 2014-07-17 EP EP14826811.3A patent/EP2929880B1/en active Active
- 2014-07-17 ES ES14826811.3T patent/ES2593527T3/es active Active
- 2014-07-17 PL PL14826811T patent/PL2929880T3/pl unknown
- 2014-07-17 LT LTEP16169414.6T patent/LT3078372T/lt unknown
- 2014-07-17 RS RS20171061A patent/RS56489B1/sr unknown
- 2014-07-17 CN CN201480040609.XA patent/CN105407887B/zh not_active Expired - Fee Related
- 2014-07-17 WO PCT/JP2014/069026 patent/WO2015008827A1/ja not_active Ceased
- 2014-07-17 DK DK16169414.6T patent/DK3078372T3/da active
- 2014-07-17 DK DK14826811.3T patent/DK2929880T3/da active
- 2014-07-17 PL PL16169414T patent/PL3078372T3/pl unknown
- 2014-07-18 TW TW103124716A patent/TWI603965B/zh active
-
2015
- 2015-08-27 JP JP2015167851A patent/JP6060231B2/ja active Active
-
2016
- 2016-01-11 IL IL243550A patent/IL243550B/en active IP Right Grant
- 2016-04-19 US US15/132,892 patent/US9918963B2/en not_active Expired - Fee Related
- 2016-04-19 US US15/132,981 patent/US20160228406A1/en not_active Abandoned
- 2016-10-25 CY CY20161101077T patent/CY1118140T1/el unknown
-
2017
- 2017-02-03 SM SM201700080T patent/SMT201700080B/it unknown
- 2017-09-26 CY CY20171101008T patent/CY1119496T1/el unknown
- 2017-10-05 HR HRP20171497TT patent/HRP20171497T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7126940B2 (ja) | 補体活性のモジュレーター | |
| CN101820848B (zh) | 抑制n-酰基乙醇胺水解性酸酰胺酶的组合物和方法 | |
| JP2007501775A (ja) | 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤 | |
| PT2048145E (pt) | Agente incrementando a actividade da proteína quinase c, contendo um derivado de um éter alquílico, ou um seu sal | |
| TW202106290A (zh) | 用於調節補體活性之組成物及方法 | |
| EA038932B1 (ru) | Фармацевтическая композиция, включающая дисульфид глутатиона и глутатион дисульфид s-оксид | |
| CN102325768B (zh) | 治疗疼痛和其他疾病的化合物和方法 | |
| TW201803562A (zh) | 用於纖維化之治療之wnt抑制劑 | |
| EP3078372B1 (en) | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor | |
| Gudasheva et al. | Design, synthesis, and neuroprotective effects of a dimeric dipeptide mimetic of the third loop of the nerve growth factor | |
| EP2338908A1 (fr) | Peptides comportant des modifications de type post-translationnel et leur utilisation dans le cadre du traitement de pathologies auto-immunes | |
| HK1222556B (en) | Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor | |
| CN115697316A (zh) | 加巴喷丁和酮洛芬的协同掺加物、药物组合物及其医疗用途 | |
| BR112021012449A2 (pt) | Agente para promoção da função de advilina, derivado de amina cíclica, e, medicamento |